Navigation Links
Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger
Date:12/4/2008

." Such statements include, but are not limited to, statements regarding the proposed transaction, including the timing for closing, the completion of MMR's audited financial statements, the benefits to Favrille's stakeholders, the benefits provided by MMR's products, including cost reductions, improved care and reduced medical errors, proposed reforms to the U.S. healthcare system, MMR's initiatives and the prices for its products following the merger and Favrille's ability to settle creditor claims. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, the risk that Favrille and MMR may not be able to complete the proposed transaction in a timely manner or at all, the risk MMR's products are not adopted or viewed favorably by the healthcare community, risks related to the current uncertainty and instability in financial and lending markets, risks related to the listing status of Favrille's common stock on the OTC Bulletin Boards, risks relating to Favrille's ability to negotiate settlements with its creditors, risks relating to the ability of Favrille and MMR to satisfy conditions to closing the proposed merger transaction and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. The combined company will also be subject to a number of risks and uncertainties, including risks relating to the need to have access to additional capital to finance the business until it can generate sufficient cash flow from operations and risks relating to the adoption of personal health care records and the development of a viable revenue generating business model. All forward-looking statements are qualified in their entirety by this cautionary statement. Favr
'/>"/>
SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction
2. Favrille Announces Receipt of Nasdaq Letters
3. Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
4. Favrille Announces Workforce Reduction
5. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
6. Favrille Reports First Quarter 2008 Financial Results
7. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. Favrille Announces $21.1 Million Registered Direct Offering
10. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
11. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a ... check the legal requirements around using controlled substances in ... , As their international operations expand and become increasingly ... built as a result of the first phase of ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014  United Therapeutics ... Medtronic, Inc. (NYSE: MDT ) has submitted ... Drug Administration (FDA) for the use of Medtronic,s SynchroMed ... newly developed catheter) for use with United Therapeutics, Remodulin ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... (Nasdaq: OREX ), a biopharmaceutical company focused on ... third quarter ended September 30,2010 on Wednesday, November 3, 2010 ... a live webcast and conference call at 5:00 p.m. Eastern ... and webcast to discuss financial results and recent business highlights. ...
... (Nasdaq: UTHR ) today announced its results of operations ... for the third quarter of 2010 were $171.0 million, up from ... the third quarter of 2010 was $39.7 million, or $0.70 per ... per basic share, for the same quarter in 2009. Gross margin ...
... the Human Genome -- REYKJAVIK, Iceland, October 27, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Biology Technology:United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 2United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 3United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 4United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 5United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 6United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 7The New deCODE Map of the Human Genome 2The New deCODE Map of the Human Genome 3The New deCODE Map of the Human Genome 4The New deCODE Map of the Human Genome 5The New deCODE Map of the Human Genome 6The New deCODE Map of the Human Genome 7The New deCODE Map of the Human Genome 8The New deCODE Map of the Human Genome 9
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 Based on ... Samsung introduces for the first time a fingerprint sensor ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ...
(Date:12/15/2014)... Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced the ... report to their offering. ... technology used for the identification of individuals. Facial recognition ... such as nose, jaw edges, mouth, and the distance ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... A team led by a scientist at The Scripps Research ... the National Institutes of Health to uncover the workings of ... NIH since 2002. The grant is focused on innovative ... range of human diseases that include viral and bacterial infections ...
... Medicine and Hygiene,s two prestigious journals will join the Oxford ... the organizations. The journals, Transactions of the ... International Health , seek to promote and advance the study, ... in the tropics and sub-tropics. The Society plays a ...
... TREW Marketing today announced it is now certified ... the HubSpot platform, TREW can help science, engineering, and ... consistent flow of qualified leads that fuel new sales ... clients stay on the leading edge of marketing best ...
Cached Biology News:Team receives $22.5 million to shed light on the immune system 2Prestigious Royal Society of Tropical Medicine and Hygiene journals join Oxford University Press 2HubSpot Certifies TREW Marketing for Integrated Marketing Platform 2HubSpot Certifies TREW Marketing for Integrated Marketing Platform 3
The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
... Fluorescein Direct In Situ Apoptosis ... in situ by the direct ... are tagged with a directly ... provides fluorescence staining for 40 ...
... is a two color staining method ... DNA to detect apoptotic cells by flow ... and reagents required for measuring apoptosis in ... for assessing reagent performance; washing, reaction, and ...
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
Biology Products: